<DOC>
	<DOC>NCT01908972</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.</brief_summary>
	<brief_title>The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma</brief_title>
	<detailed_description>- Randomized (A group : propranolol, B group : prednisolone) - A group : 3 days admission and medication for 16 weeks - B group : medication for 16 weeks without admission - Hemangioma volume comparison by using MRI - other measurement and drug adverse reaction monitoring</detailed_description>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Hemangioma patient ( 0 ~ 9 months old) No treatment before 10 ~ 20 % volume increase in 2 ~ 4 weeks Hemangioma that caused organ function Hemangioma that will cause aesthetic problem Cardiovascular disease (impossible to use propranolol) Drug adverse reaction or allergy history (propranolol, steroid) Bradycardia, Atrioventricular block, atrial block Cardiogenic Shock Right heart failure (pulmonary hypertension) Congestive heart failure Hypotension Peripheral nerve disease (moderate) Angina Hormone deficiency patient Pulmonary disease (asthma) diabetic ketoacidosis laser treatment history</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Months</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hemangioma</keyword>
	<keyword>Propranolol</keyword>
	<keyword>prednisolone</keyword>
	<keyword>steroid</keyword>
</DOC>